Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

metaMe Health Receives FDA Clearance for Regulora®, the First FDA-authorized Treatment Specifically for Abdominal Pain Due to Irritable Bowel Syndrome (IBS)

Abdominal pain is the primary symptom of all IBS subtypes (IBS-C, IBS-D, and IBS-M), and is the number one reason patients seek treatment for their IBS. Regulora® is a prescription Digital Therapeutic (PDT) that is self-administered through an Apple or Android smartphone.


News provided by

metaMe Health

Nov 30, 2021, 14:30 ET

Share this article

Share toX

Share this article

Share toX

metaMe Health is committed to developing FDA-cleared Prescription Digital Therapeutics (PDT) for the treatment of gastrointestinal conditions.
metaMe Health is committed to developing FDA-cleared Prescription Digital Therapeutics (PDT) for the treatment of gastrointestinal conditions.

CHICAGO, Nov. 30, 2021 /PRNewswire-PRWeb/ -- metaMe Health, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for Regulora®, the first FDA-authorized treatment of any kind specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults.

Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice. The COVID-19 pandemic has prevented patients from engaging in many of the activities of daily living and has led to increases in pain and psychological distress due to IBS-related symptoms (1). This has created a growing unmet medical need for self-administered behavioral therapy options to treat IBS.

IBS is a widespread and debilitating condition that arises partially from miscommunication between the brain and the gut. Treatments like Regulora aim to normalize brain-gut communication.

Post this

Regulora provides behavioral therapy based on Gut-Directed Hypnotherapy (GDH) through a convenient smartphone app that can be used at home. GDH helps patients with their IBS symptoms by promoting healthier control of digestive tract function and delivering therapy designed to influence pain sensation (2). Until now, GDH has been provided only in-person by licensed therapists.

"The FDA's clearance of Regulora, our first PDT, is a major achievement for the company," said Tim Rudolphi, CEO of metaMe Health. "We are eager to expand access of this proven therapy to patients with all three subtypes of IBS."

Regulora provides a valuable treatment option for IBS patients and their physicians. "Decades of studies show that GDH administered in person by therapists is effective in treating IBS symptoms. However, few therapists are trained in this highly specialized technique, so this option has not been available to most patients. Regulora now makes this treatment accessible to any adult with IBS through their regular doctor or GI specialist, and also makes it far more convenient because no therapist visits are needed," said Dr. Olafur Palsson, Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina.

Irritable Bowel Syndrome is a chronic condition of the lower gastrointestinal tract that affects 10-15% of adults in the United States. IBS accounts for nearly 3.5 million physician visits in the U.S. annually and is one of the most common diagnosis made by gastroenterologists (3).

"IBS is a widespread and debilitating condition that arises partially from miscommunication between the brain and the gut. Stress and other external factors can contribute to normal gut signals being amplified and misinterpreted by the brain as abdominal pain. Treatments like Regulora aim to normalize brain-gut communication," explained Dr. Neil Sengupta, Assistant Professor of Gastroenterology at the University of Chicago Pritzker School of Medicine.

About Regulora

Regulora is a digital therapeutic mobile app that is downloaded onto an Apple or Android mobile device. Regulora provides for seven 30-minute sessions of remote behavioral therapy based on Gut-Directed Hypnotherapy (GDH) that are administered over a period of 12 weeks. Prior to Regulora, GDH therapy would be provided only via a trained clinician in a medical clinic. With Regulora, video GDH treatment sessions are presented on your mobile device.

GDH provided in the clinic by trained therapists has been shown in numerous studies to help patients improve their IBS symptoms, including abdominal pain, constipation, diarrhea, and bloating. According to a 2020 systematic review of the scientific research, among the behavioral treatments for IBS, GDH has strong evidence of effectiveness and produces long-lasting beneficial effects (4).

Clinical Evidence Supporting Regulora

Regulora was evaluated in a multi-site, randomized, controlled, and blinded clinical trial of 362 evaluable subjects. Two of three analyses of the primary endpoint of abdominal pain achieved clinically significant separation from the control arm. Additionally, 68% of subjects assigned to Regulora reported overall satisfaction with the treatment and 87% would recommend Regulora to someone else with IBS. No serious adverse events were associated with Regulora. About 1% of study participants experienced non-serious adverse events including abdominal pain, constipation, fatigue, or headache. 87% of subjects assigned to Regulora were adherent to therapy.

Regulora Indications for Use

Regulora is a prescription-only digital therapeutic device intended to provide behavioral therapy through gut-directed hypnotherapy for adults 22 years of age and older who have been diagnosed with Irritable Bowel Syndrome (IBS). Regulora is indicated as a 3-month treatment for patients with abdominal pain due to IBS and is intended to be used together with other IBS treatments.

About IBS

Irritable Bowel Syndrome is a chronic condition that affects 10-15% of adults in the United States. The central symptom is abdominal pain, which is accompanied by diarrhea (IBS-D), constipation (IBS-C), or mixed periods (IBS-M). IBS has a severe impact on quality of life; IBS sufferers say they would give 25% of their remaining life (an average of 15 years) to live symptom-free, according to a survey of nearly 2000 patients (5). Symptoms are mediated by a dysregulation of the sensory and motility signaling between the brain and the gut and exacerbated by cognitive, behavioral, affective, and physiologic factors. The annual cost of IBS treatment in the United States has been estimated to be between $1.7 billion and $10 billion in direct costs, with total indirect costs of $20 billion (6).

References
(1) Kamp et al. J Clin Gastroenterology. 2021; PMID:33780216.
(2) Palsson OS. Am J Clin Hypn. 2015; PMID: 26264539.
(3) International Foundation for Gastrointestinal Disorders (IFFGD) Facts About IBS (https://aboutibs.org/what-is-ibs/facts-about-ibs/statistics/).
(4) Black et al. Gut. 2020; PMID: 32276950.
(5) Gastrointestinal Society IBS Global Impact Report 2018 (https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf).
(6) Hulisz, D., J Managed Care Pharm, 2004. PMID 15298528.

About metaMe Health, Inc.

metaMe Health is committed to developing FDA-cleared Prescription Digital Therapeutics (PDT) for the treatment of gastrointestinal conditions. Prescription Digital Therapeutics are software applications that deliver evidence-based therapeutic interventions to patients to prevent or treat a medical disorder or disease. They are used independently or in concert with medications or other therapies to optimize patient care and health outcomes. PDTs are developed under rigorous conditions complete with clinical trials, FDA clearance, and availability only through a physician's prescription.

For additional information or investor inquiries, email [email protected]

Media Contact

Tim Rudolphi, metaMe Health, +1 (888) 463-8263, [email protected]

SOURCE metaMe Health

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.